Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Climb Bio (CLYM) Enterprise Value (2021 - 2026)

Climb Bio filings provide 7 years of Enterprise Value readings, the most recent being -$109.6 million for Q1 2026.

  • Quarterly Enterprise Value fell 11.73% to -$109.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$109.6 million through Mar 2026, down 11.73% year-over-year, with the annual reading at -$101.1 million for FY2025, 33.02% up from the prior year.
  • Enterprise Value hit -$109.6 million in Q1 2026 for Climb Bio, down from -$101.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$84.7 million in Q2 2025 and bottomed at -$261.7 million in Q3 2024.
  • Average Enterprise Value over 5 years is -$153.5 million, with a median of -$150.9 million recorded in 2024.
  • The largest annual shift saw Enterprise Value tumbled 143.6% in 2024 before it surged 66.79% in 2025.
  • Climb Bio's Enterprise Value stood at -$187.4 million in 2022, then surged by 43.02% to -$106.8 million in 2023, then plummeted by 41.31% to -$150.9 million in 2024, then soared by 33.02% to -$101.1 million in 2025, then dropped by 8.39% to -$109.6 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Enterprise Value are -$109.6 million (Q1 2026), -$101.1 million (Q4 2025), and -$86.9 million (Q3 2025).